𝔖 Bobbio Scriptorium
✦   LIBER   ✦

P160 Alemtuzumab-induced apoptosis in vitro in chronic lymphocytic leukemia with p53 deletion

✍ Scribed by L. Méhes; B. Telek; L. Rejtö; A. Kiss; A. Ujfalusi; M. Udvardy

Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
46 KB
Volume
21
Category
Article
ISSN
0268-960X

No coin nor oath required. For personal study only.

✦ Synopsis

lymphocytic leukemia. Besides establishing the demographic characteristics of 322 CLL cases studied, CD38 and ZAP7o was investigated in 58 vs. 64% of the cases while in 57% of the CLL cases FISH analysis for +12,13q ,11q and 17p was possible. Results: (1) The frequency of FISH detected aberrations in 183 CLL patients showed up 20.6; 59.5;11.4 and 8.4% for +12, 13q , 11q and 17p respectively which seems to be in good concordance with literature data. (2) The occurence of ZAP 70 level >20% was more frequent in those CLL cases requiring early therapeutic interventions (1 2 years after the diagnosis).

(3) None of the FISH markers were associated with the time elapsing between the diagnosis and the start of the therapy for CLL. (4) CLL cases with long survival (> 10 years from diagnosis) have revealed an underrepresentation of 11q .

Conclusion:

Prospective studies will answer to what extent these biological parameters will have a role in the risk adopted therapy for CLL.

P160 Alemtuzumab-induced apoptosis in vitro in chronic lymphocytic leukemia with p53 deletion

📜 SIMILAR VOLUMES

Significance of phosphotyrosine proteins
Significance of phosphotyrosine proteins, Bcl-2 and p53 for apoptosis in resting b-chronic lymphocytic leukemia (CLL) cells
✍ Nongnit Laytragoon-Lewin; Eva D. Rossmann; Juan Castro; Håkan Mellstedt 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 139 KB

## Abstract Signal transduction and apoptosis in B‐cell chronic lymphocytic leukemia (CLL) cells with a post‐germinal center (GC) phenotype were studied. Specific activation of the cells was induced by a combination of soluble anti‐CD40 monoclonal antibody and interleukin‐4 (CD40/IL‐4) and nonspeci

Alemtuzumab as treatment for residual di
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia
✍ Susan M. O'Brien; Hagop M. Kantarjian; Deborah A. Thomas; Jorge Cortes; Francis 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views

## Abstract ## BACKGROUND The objective of this study was to investigate the efficacy and safety of alemtuzumab, the humanized anti‐CD52 monoclonal antibody, in patients with B‐cell chronic lymphocytic leukemia and residual disease after chemotherapy. ## METHODS Forty‐one patients received alemt